This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALXN Alexion Pharmaceuticals (ALXN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Alexion Pharmaceuticals Stock (NASDAQ:ALXN) 30 days 90 days 365 days Advanced Chart Get ALXN alerts:Sign Up Key Stats Today's Range$182.50▼$182.5050-Day Range$179.45▼$186.6152-Week Range$99.91▼$187.45Volume10 shsAverage Volume3.31 million shsMarket Capitalization$40.34 billionP/E Ratio59.64Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAlexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.Read More… Alexion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreALXN MarketRank™: Alexion Pharmaceuticals scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Alexion Pharmaceuticals. Earnings and Valuation1.9 / 5Proj. Earnings Growth6.12% Earnings GrowthEarnings for Alexion Pharmaceuticals are expected to grow by 6.12% in the coming year, from $13.08 to $13.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alexion Pharmaceuticals is 59.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Alexion Pharmaceuticals is 59.64, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.75.Price to Earnings Growth RatioAlexion Pharmaceuticals has a PEG Ratio of 0.93. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlexion Pharmaceuticals has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ALXN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlexion Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlexion Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-1.88 Short InterestThere is no current short interest data available for ALXN. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Alexion Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alexion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.03% of the stock of Alexion Pharmaceuticals is held by insiders.Percentage Held by Institutions82.94% of the stock of Alexion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alexion Pharmaceuticals' insider trading history. Receive ALXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alexion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALXN Stock News HeadlinesAlexion Stock Price HistoryJune 23 at 10:15 PM | investing.comAlexion’s ravulizumab granted FDA orphan designationMarch 18, 2025 | markets.businessinsider.comWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.June 24, 2025 | Crypto Swap Profits (Ad)Alexion, DHL partner for sustainable air delivery of medicine in IrelandFebruary 14, 2025 | msn.comMonopar's Incredible Journey From $5 To $50 In Less Than 5 MonthsFebruary 6, 2025 | markets.businessinsider.comMonopar Therapeutics Stock Hits 52-Week High at $38.91January 23, 2025 | msn.comAstraZeneca's Alexion Inks Deal With Pan-Canadian Pharmaceutical AllianceDecember 18, 2024 | markets.businessinsider.comMonopar Therapeutics Secures License for Wilson Disease TreatmentOctober 25, 2024 | finance.yahoo.comSee More Headlines ALXN Stock Analysis - Frequently Asked Questions How were Alexion Pharmaceuticals' earnings last quarter? Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings results on Thursday, April, 29th. The biopharmaceutical company reported $3.52 EPS for the quarter, beating the consensus estimate of $3.16 by $0.36. The firm's quarterly revenue was up 13.3% compared to the same quarter last year. Does Alexion Pharmaceuticals have any subsidiaries? Alexion Pharmaceuticals subsidiaries include Portola Pharmaceuticals Inc., Achillion Pharmaceuticals, Syntimmune, Wilson Therapeutics, Synageva BioPharma Corp., Enobia Pharma Corp., Taligen Therapeutics Inc., and others. What other stocks do shareholders of Alexion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alexion Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Tesla (TSLA), Netflix (NFLX), Gilead Sciences (GILD) and Alibaba Group (BABA). Company Calendar Last Earnings4/29/2021Today6/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALXN CIK899866 Webwww.alexion.com Phone475-230-2596FaxN/AEmployees3,837Year Founded1992Profitability EPS (Most Recent Fiscal Year)$11.60 Trailing P/E Ratio59.64 Forward P/E Ratio13.95 P/E Growth0.93Net Income$603.40 million Net Margins10.89% Pretax MarginN/A Return on Equity23.43% Return on Assets15.06% Debt Debt-to-Equity Ratio0.19 Current Ratio4.52 Quick Ratio3.96 Sales & Book Value Annual Sales$6.07 billion Price / Sales6.65 Cash Flow$22.81 per share Price / Cash Flow8.00 Book Value$53.24 per share Price / Book3.43Miscellaneous Outstanding Shares221,019,000Free FloatN/AMarket Cap$40.34 billion OptionableOptionable Beta1.25 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ALXN) was last updated on 6/24/2025 by MarketBeat.com Staff From Our PartnersSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | Sponsored12 “perfect” stocksJoin the Dream Team and see how we can guarantee stock market wins Credentials are a good thing, especiall...Zacks | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alexion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alexion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.